サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1344495

転移性がん治療薬市場：治療法別、適応症別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Metastatic Cancer Drugs Market By Therapy, By Indication, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日
ページ情報
英文 313 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
転移性がん治療薬市場：治療法別、適応症別、流通チャネル別：世界の機会分析と産業予測、2023-2032年
出版日: 2023年06月01日
発行: Allied Market Research
ページ情報: 英文 313 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Allied Market Researchが発行した最新レポート「転移性がん治療薬市場」によると、転移性がん治療薬市場は2022年に677億米ドルと評価され、2023年から2032年にかけてCAGR 7.3%で成長し、2032年には1,369億米ドルに達すると推定されています。

転移性がんはステージIVがんとも呼ばれ、元の部位（原発腫瘍）から体の他の部位に転移したがんを表す用語です。がん細胞が近くの組織に浸潤し、血流やリンパ系に入り、異なる場所に新たな腫瘍を形成する能力は、転移性がんの複雑さを助長しています。転移性がんに対する一般的な治療アプローチには、化学療法、ホルモン療法、標的療法、免疫療法などの全身療法があります。

Metastatic Cancer Drugs Market-IMG1

さらに、転移性がんは乳がん、肺がん、結腸がん、前立腺がん、黒色腫など様々な種類の原発腫瘍から発生する可能性があります。最も一般的な転移部位は、肺、肝臓、骨、脳、リンパ節などです。また、転移がんは限局がんに比べ、より重篤で課題も多いとされています。予後が悪く、治療の選択肢も少なくなります。がん細胞が遠隔部位に広がることで、病気を完全に根絶することが難しくなります。転移性がんの症状や徴候は、転移の場所や大きさによって異なります。一般的な症状としては、体重減少、特定の部位の持続的な痛み、息切れ、疲労感、脳が侵されている場合は神経症状などがあります。

転移性がん治療薬市場の成長を促進する主な要因は、研究開発の進歩、転移性がんの有病率の増加、個別化医療に対する需要の急増、老人人口の増加、政府の支援策です。世界の転移性がんの罹患率と有病率の急増は、市場成長の重要な促進要因となっています。例えば、乳がん研究財団（BCRF）が2022年に発表した記事によると、米国では女性の6～10％がステージ4の乳がんと診断され、早期乳がんと診断された女性の30％近くが転移性乳がんに罹患する可能性があります。転移性がんと診断される患者数の急増に伴い、進行期がん特有の課題に対処する効果的な薬剤の開発と入手が必要となっています。

さらに、進行中の研究開発努力が転移性がん治療薬市場の成長を促進する上で重要な役割を果たしています。分子生物学、ゲノミクス、標的治療における発見により、転移を引き起こす分子メカニズムを特異的に標的とする革新的な薬剤が開発されています。創薬技術の進歩により、新たな薬物標的が同定され、これらの標的を選択的に阻害する化合物が開発され、有効性の向上と毒性の軽減につながっています。例えば、チロシンキナーゼ阻害剤（TKI）などの標的療法は、がんの増殖と進行に関与する特定の分子標的を阻害することで、特定のタイプの転移性がんの治療に顕著な成功を示しています。このような進歩が、市場におけるより新しく、より効果的な薬剤の需要を後押ししています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • がんの検出と診断の進歩
      • 転移性がんの有病率の増加
      • 個別化医療の採用急増
    • 抑制要因
      • 抗がん剤使用に伴う副作用
    • 機会
      • 未開発の新興国における高い成長の可能性
      • パイプライン医薬品の増加
  • COVID-19による市場への影響分析

第4章 転移性がん治療薬市場：治療法別

  • 化学療法
  • ホルモン療法
  • 標的療法
  • 免疫療法

第5章 転移性がん治療薬市場：適応症別

  • 乳がん
  • 肺がん
  • 前立腺がん
  • 大腸がん
  • 黒色腫
  • その他

第6章 転移性がん治療薬市場：流通チャネル別

  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンラインプロバイダー

第7章 転移性がん治療薬市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ
    • ブラジル
    • サウジアラビア
    • 南アフリカ
    • その他の地域

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第9章 企業プロファイル

  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Novartis AG
  • Eli Lilly and Company.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Amgen Inc.
  • Sanofi S.A.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 02. METASTATIC CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. METASTATIC CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. METASTATIC CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. METASTATIC CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 07. METASTATIC CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. METASTATIC CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. METASTATIC CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. METASTATIC CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. METASTATIC CANCER DRUGS MARKET FOR MELANOMA, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. METASTATIC CANCER DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 14. METASTATIC CANCER DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. METASTATIC CANCER DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. METASTATIC CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. METASTATIC CANCER DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 22. U.S. METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 23. U.S. METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 24. U.S. METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. CANADA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 26. CANADA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 27. CANADA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. UK METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 42. UK METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 43. UK METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. ITALY METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 45. ITALY METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 46. ITALY METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 58. JAPAN METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 59. JAPAN METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 60. CHINA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 61. CHINA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 62. CHINA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 63. INDIA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 64. INDIA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 65. INDIA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 67. AUSTRALIA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 68. AUSTRALIA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 73. REST OF ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 74. REST OF ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. LAMEA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 76. LAMEA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 77. LAMEA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. LAMEA METASTATIC CANCER DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 80. BRAZIL METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 81. BRAZIL METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 82. SAUDI ARABIA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 83. SAUDI ARABIA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 84. SAUDI ARABIA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 85. SOUTH AFRICA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 86. SOUTH AFRICA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH AFRICA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LAMEA METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022-2032 ($MILLION)
  • TABLE 89. REST OF LAMEA METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 90. REST OF LAMEA METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 96. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 97. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 98. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 99. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 100. MERCK & CO., INC.: KEY STRATERGIES
  • TABLE 101. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 102. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 103. ASTRAZENECA PLC: PRODUCT SEGMENTS
  • TABLE 104. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 105. ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 106. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 107. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 108. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 109. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 110. NOVARTIS AG: KEY STRATERGIES
  • TABLE 111. ELI LILLY AND COMPANY.: KEY EXECUTIVES
  • TABLE 112. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 113. ELI LILLY AND COMPANY.: PRODUCT SEGMENTS
  • TABLE 114. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 115. ELI LILLY AND COMPANY.: KEY STRATERGIES
  • TABLE 116. PFIZER INC.: KEY EXECUTIVES
  • TABLE 117. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 118. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 119. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 120. PFIZER INC.: KEY STRATERGIES
  • TABLE 121. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 122. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 123. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 125. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 126. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 127. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 128. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 129. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 130. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 131. AMGEN INC.: KEY EXECUTIVES
  • TABLE 132. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 133. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 134. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 135. AMGEN INC.: KEY STRATERGIES
  • TABLE 136. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 137. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 138. SANOFI S.A.: PRODUCT SEGMENTS
  • TABLE 139. SANOFI S.A.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. METASTATIC CANCER DRUGS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF METASTATIC CANCER DRUGS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN METASTATIC CANCER DRUGS MARKET (2023-2032)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. HIGH BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMETASTATIC CANCER DRUGS MARKET
  • FIGURE 09. METASTATIC CANCER DRUGS MARKET, BY THERAPY, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR IMMUNOTHERAPY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. METASTATIC CANCER DRUGS MARKET, BY INDICATION, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR BREAST CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR LUNG CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR PROSTATE CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR MELANOMA, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF METASTATIC CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. METASTATIC CANCER DRUGS MARKET BY REGION, 2022
  • FIGURE 26. U.S. METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. CANADA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. MEXICO METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. GERMANY METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. FRANCE METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. UK METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. ITALY METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SPAIN METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF EUROPE METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. JAPAN METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. CHINA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. INDIA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. AUSTRALIA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH KOREA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF ASIA-PACIFIC METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. BRAZIL METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SAUDI ARABIA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. SOUTH AFRICA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF LAMEA METASTATIC CANCER DRUGS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: METASTATIC CANCER DRUGS MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2022
  • FIGURE 52. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. MERCK & CO., INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 59. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 65. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 68. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 69. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 71. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 72. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 73. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 74. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 75. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 76. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A109351

According to a new report published by Allied Market Research, titled, "Metastatic Cancer Drugs Market," The metastatic cancer drugs market was valued at $67.7 billion in 2022, and is estimated to reach $136.9 billion by 2032, growing at a CAGR of 7.3% from 2023 to 2032. Metastatic cancer, also referred to as stage IV cancer, is a term used to describe cancer that has spread from its original site (primary tumor) to other parts of the body. The ability of cancer cells to invade nearby tissues, enter the bloodstream or lymphatic system, and establish new tumors in different locations contributes to the complexity of metastatic cancer. Common treatment approaches for metastatic cancer include systemic therapies such as chemotherapy, hormonal therapy, targeted therapy and immunotherapy.

Metastatic Cancer Drugs Market - IMG1

Moreover, metastatic cancer can arise from various types of primary tumors such as breast, lung, colon, prostate, and melanoma. The most common sites of metastasis include the lungs, liver, bones, brain, and lymph nodes. In addition, metastatic cancer is considered as more severe and challenging stage than localized cancer. It is associated with poorer prognosis and reduced treatment options. The spread of cancer cells to distant sites makes it difficult to eradicate the disease completely. The symptoms and signs of metastatic cancer vary depending on the location and size of the metastasis. Common symptoms may include weight loss, persistent pain in specific areas, shortness of breath, fatigue, and neurological symptoms if the brain is affected.

The major factors that drive the growth of metastatic cancer drugs market are advancements in R&D, increase in prevalence of metastatic cancer, surge in demand for personalized medicine, rise in geriatric population, and supportive government initiatives. The surge in incidence and prevalence of metastatic cancer worldwide serves as a significant driver for market growth. For instance, an article published by Breast Cancer Research Foundation (BCRF) in 2022, stated that, 6 to 10% of women are diagnosed with stage 4 breast cancer in the U.S., and nearly 30 percent of women diagnosed with early-stage breast cancer may suffer from metastatic stage cancer. The upsurge in number of individuals diagnosed with metastatic cancer necessitates the development and availability of effective drugs to address the specific challenges associated with advanced stage disease.

Further, ongoing R&D efforts play a crucial role in driving the metastatic cancer drugs market growth. Discoveries in molecular biology, genomics, and targeted therapies have led to the development of innovative drugs that specifically target the molecular mechanisms driving metastasis. Advancements in drug discovery techniques have led to the identification of new drug targets and the development of compounds that selectively inhibit these targets, leading to improved efficacy and reduced toxicity. For instance, targeted therapies, such as tyrosine kinase inhibitors (TKIs), have shown remarkable success in treating specific types of metastatic cancers by inhibiting specific molecular targets involved in cancer growth and progression. These advancements drive the demand for newer and more effective drugs in the market.

In addition, R&D efforts have focused on developing combination therapies involving the simultaneous use of multiple drugs with complementary mechanisms of action. Combination therapies can enhance treatment response, overcome drug resistance, and improve patients' outcomes. Furthermore, development of novel drug delivery systems enhances the efficacy and safety of metastatic cancer drugs. Advanced drug delivery technologies such as nanotechnology-based formulations, targeted drug delivery systems, and combination therapies enable better drug targeting, reduced toxicity, and improved treatment outcomes. These innovations contribute to the growth of the metastatic cancer drugs market. Moreover, government initiatives such as funding for research, development, and accessibility of metastatic cancer drugs is anticipated to propel the market growth. Public funding, grants, and collaborations with academic institutions and pharmaceutical companies facilitate the discovery and development of novel drugs and treatment approaches. These initiatives aim to improve patient access to affordable metastatic cancer drugs, further driving the market growth.

In addition, increased awareness and education about metastatic cancer and its treatment options contribute to the market growth. Patient and caregiver advocacy groups, awareness campaigns, and educational programs help in promoting early detection, timely diagnosis, and appropriate treatment for metastatic cancer. This heightened awareness drives the demand for metastatic cancer drugs and improves patient outcomes. The metastatic cancer drugs market is segmented on the basis of therapy, indication, distribution channel, and region. On the basis of therapy, the market is categorized into chemotherapy, hormonal therapy, targeted therapy, and immunotherapy. On the basis of indication, the market is classified into breast cancer, lung cancer, prostate cancer, colorectal cancer, melanoma, and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global metastatic cancer drugs market are Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Amgen Inc., Sanofi S.A. and F. Hoffmann-La Roche Ltd. The key players have adopted strategies such as collaboration, product launch, new product development, and product approval to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the metastatic cancer drugs market analysis from 2022 to 2032 to identify the prevailing metastatic cancer drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the metastatic cancer drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global metastatic cancer drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy

  • Chemotherapy
  • Hormonal therapy
  • Targeted therapy
  • Immunotherapy

By Indication

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

By Distribution channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Amgen Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company.
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. High bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Advancements in cancer detection and diagnosis
      • 3.4.1.2. Increase in prevalence of metastatic cancer
      • 3.4.1.3. Surge in adoption of personalized medicine
    • 3.4.2. Restraints
      • 3.4.2.1. Adverse effects associated with the use of cancer drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in untapped emerging economies
      • 3.4.3.2. Increase in number of pipeline drugs
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: METASTATIC CANCER DRUGS MARKET, BY THERAPY

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Chemotherapy
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Hormonal therapy
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Targeted therapy
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Immunotherapy
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: METASTATIC CANCER DRUGS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Breast Cancer
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Lung Cancer
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Prostate Cancer
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Colorectal Cancer
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country
  • 5.6. Melanoma
    • 5.6.1. Key market trends, growth factors and opportunities
    • 5.6.2. Market size and forecast, by region
    • 5.6.3. Market share analysis by country
  • 5.7. Others
    • 5.7.1. Key market trends, growth factors and opportunities
    • 5.7.2. Market size and forecast, by region
    • 5.7.3. Market share analysis by country

CHAPTER 6: METASTATIC CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Store and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: METASTATIC CANCER DRUGS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Therapy
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Therapy
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Therapy
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Therapy
      • 7.2.5.3.3. Market size and forecast, by Indication
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Therapy
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Therapy
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Therapy
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Therapy
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Therapy
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Therapy
      • 7.3.5.5.3. Market size and forecast, by Indication
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Therapy
      • 7.3.5.6.3. Market size and forecast, by Indication
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Therapy
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Therapy
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Therapy
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Therapy
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Therapy
      • 7.4.5.4.3. Market size and forecast, by Indication
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Therapy
      • 7.4.5.5.3. Market size and forecast, by Indication
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Therapy
      • 7.4.5.6.3. Market size and forecast, by Indication
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Therapy
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Therapy
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Therapy
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Therapy
      • 7.5.5.3.3. Market size and forecast, by Indication
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Therapy
      • 7.5.5.4.3. Market size and forecast, by Indication
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Bristol-Myers Squibb Company
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Merck & Co., Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. AstraZeneca plc
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Eli Lilly and Company.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Pfizer Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. F. Hoffmann-La Roche Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Johnson & Johnson
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Amgen Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Sanofi S.A.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance